Keytruda trial for untreated lymphoma halted early
NCT ID NCT03498612
First seen Nov 12, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very little data on how well it worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda)
What this could lead to
If it had succeeded, this could have pointed toward an immunotherapy option for untreated follicular and marginal zone lymphoma, potentially delaying the need for chemotherapy.
What could go wrong
The trial was terminated early with only 9 participants, so results are very limited. Pembrolizumab can cause immune-related side effects, and it is unclear if it works as a first treatment for these lymphomas.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.